Krystal Biotech (KRYS) Fundamental Analysis: Revenue, Earnings & Valuation

3.52 / 10

Netural

Fundamental analysis rates KRYS as neutral with a 3.5/10 score. Revenue‑MV and Profit‑MV are relatively strong, but Asset‑MV and income‑tax ratios are weak. Margins and asset efficiency are low, suggesting limited growth potential and a guarded outlook.

Analysis Checks(6/10)

Revenue-MV

Value-1.95

Score2/3

Weight46.57%

1M Return8.05%

Inventory turnover ratio

Value0.69

Score2/3

Weight-2.44%

1M Return-0.56%

Gross profit margin (%)

Value94.08

Score0/3

Weight-19.31%

1M Return-5.42%

Profit-MV

Value0.32

Score2/3

Weight37.90%

1M Return6.36%

Income tax / Total profit (%)

Value-8.11

Score1/3

Weight0.93%

1M Return0.21%

Current assets turnover ratio

Value0.44

Score1/3

Weight-0.83%

1M Return-0.17%

Fixed assets turnover ratio

Value2.54

Score2/3

Weight0.05%

1M Return0.01%

Cost of sales ratio (%)

Value5.92

Score2/3

Weight-15.53%

1M Return-3.62%

Asset-MV

Value-0.55

Score0/3

Weight15.55%

1M Return2.73%

Cash-MV

Value-0.81

Score2/3

Weight37.13%

1M Return6.19%

Is KRYS fundamentally strong?

KRYS scores 3.52/10 on fundamentals and holds a Fair valuation at present. Backed by its 18.91% ROE, 52.64% net margin, 35.22 P/E ratio, 5.91 P/B ratio, and 126.92% earnings growth, these metrics solidify its Netural investment rating.